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Abstract 
OBJECTIVES:  
Immune activation, among other driven by IFN-α and -γ activation is a main feature of 
progressive HIV infection.  Suppressor of cytokine signaling (SOCS) 1 and 3 are negative 
feedback regulators of the IFN-α and -γ axis. Here, we analyzed the role of 9 single nucleotid  
polymorphisms (SNPs) within SOCS-1 and 3 genes for their association with HIV 
progression rate in a cohort of 318 rapid vs 376 slow progressors from the Swiss HIV Cohort 
Study. 
DESIGN AND METHODS:  
We analyzed 9 SNPs, which we have identified in Swiss blood donors, in a cohort of HIV-
infected patients (n=1144), which have been categorized according to the decline in CD4+ T-
cell counts. In all the conducted analyses, we focused on the comparison between rapid and 
slow progressors with regard to SNPs in SOCS1 and -3 and with regards to haplotypes using 
multivariate logistic regression models. 
RESULTS:  
Three SOCS-1 SNPs (rs193779; rs33989964; and rs4780355) are associated with a risk 
reduction for rapid progression. Two of these SNPs, rs33989964 and rs4780355, are in strong 
linkage disequilibrium forming a frequent haplotype. Homozygous carriers of this haplotype 
are also associated with a risk reduction for rapid progression. In contrast, the minor TT 
genotype of rs33977706 is associated with twice the risk for rapid progression. No 
associations have been observed for the four SOCS-3 SNPs or the major SOCS-3 haplotypes.  
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CONCLUSION:  
Our data suggest that SNPS in SOCS-1 are associated with HIV disease progression and 
speak in favor that immune activation is causal for the progressive immunodeficiency.  
Keywords: HIV, immune activation, IFN-alpha, IFN-gamma, SOCS, single-nucleotide 
polymorphisms 
 
Background: 
Hallmark of HIV pathogenesis is sustained immune activ tion and dysfunction [1]. Chronic 
antigen stimulation, microbial translocation and stimulation of the innate immune response [2], 
all, may contribute to this phenomenon.  In this context, we note sustained interferon (IFN) 
type I signaling in chronic HIV infection [3]. Indeed, IFN plasma levels correlated with the 
plasma viral load and inversely with the CD4+ T-cell count [4]. This goes together with a 
relative overexpression of IFN stimulated genes (ISGs). A model has been postulated on the 
basis of these findings that HIV promotes IFN signaling, in turn IFN promotes the activation 
and proliferation of CD4+ T-cells and thereby increas s the number of HIV target cells while 
resulting in immune dysfunction and exhaustion [3]. Alternatively, these findings of increased 
IFN signaling might simply be interpreted as an epiphenomenon of higher viral replication 
and advanced disease state. In SIV infected rhesus macaques, the administration of IFN-α2 
continued beyond the acute phase resulted in an IFN-desensitized state with decreased anti-
viral gene expression, increased susceptibility to infection, increased cell-associated virus 
load and greater CD4+ T-cell depletion [5]. In chronically HIV-infected humanized mice, 
blocking the Interferon receptor (IFNAR) resulted in increased viral replication but rescued 
both total human T-cell and HIV-specific T-cell numbers [6]. Similarly, blocking IFNAR in 
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HIV-infected humanized mice under suppressive combined anti-retroviral treatment restored 
immune function [6, 7]. These data would rather favor a causal role of chronic IFN activation in 
HIV pathogenesis. Notably, chronic IFN activation being at the origin of persistent infections 
has been convincingly demonstrated in the lymphocytic horiomeningitis model [8]. 
Apart of chronic IFN type I activation, low levels of IFN-γ are detected throughout the course 
of HIV infection [9]. It appears that IFN-γ expression has no predictive value for either HIV 
viral set point, mortality, or disease progression rate. Based on its poly-functional effects on 
immune responses, IFN-γ was even explored as treatment strategy for HIV/AIDs but had no 
therapeutic efficacy [9]. In contrast, IFN-γ induced protein 10 (IP10 or CXCL10) which is 
driven predominantly by IFN-γ shows increased plasma levels in HIV infection [10]. Most 
studies reported a positive correlation between IP-10 levels and disease progression rate [10]. 
High IP-10 levels suppress the functions of T-cells and NK cells and promote HIV latency 
and replication [10]. Notably, to what extent, IFN-γ adds to the HIV-associated immune 
activation remains largely unknown.   
IFN type I and IFN-γ signal via their Jak/STAT pathway following binding to their cognate 
IFN receptor which results in the up-regulation of hundreds of IFN stimulated genes [11]. 
Effective immune responses to pathogens needs a fine tu ed regulation of pro- and anti-
inflammatory factors. Else, undamped immune activation results in excessive 
immunopathology. Thus, already in the first wave of ISGs, negative feedback regulators to 
the IFN axis are up-regulated, among others suppresso  of cytokine signaling (SOCS) [12].  
SOCS proteins inhibit signal transducer and activator of transcription proteins (STATs) 
phosphorylation by binding and inhibiting Janus kinases, by their increased proteosomal 
degradation or by competing with STATs for phosphotyrosine binding sites on cytokine 
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receptors [13, 14]. The family of SOCS proteins consist of eight membrs, including SOCS1-7 
and cytokine inducible Src homology2 (SH2)-containing protein (CIS). Mice lacking SOCS-1 
show features reminiscent of HIV pathogenesis, i.e.d struction of the lymphoid organs, a 
loss of CD4+ T-cells and sustained immune activation. SOCS are ve y short-lived proteins 
and their quantification is very delicate. A number of studies reported that HIV results in 
increased expression of SOCS at the mRNA level but they did not measure it at the protein 
level. They concluded that SOCS is increased in HIV and attenuates the anti-HIV IFN 
response [15-18]. In contrast we found that HIV-infected patients have lower SOCS protein 
levels than matched controls and interpreted the data th t HIV interferes with negative SOCS 
feedback mechanisms [19]. 
Here, we hypothesized that functionally different human SOCs alleles underlie the distinct 
HIV progression rate, i.e., SOCS with higher activity might attenuate IFN signaling thereby 
lessening the immune activation state. Notably, HIV-infected patients commonly progress 
from transmission to late stage disease with < 200 CD4+ T cells/µl within 7.5 - 12 years. 
However, HIV-infected patients may show a very rapid d sease progression rate (3-4 years 
from transmission to the AIDS phase) or be long-term non progressors [20]. LTNP are often 
asymptomatic for 10 to 20 years with CD4+ T-cell counts > 500 cells/µl. Because the chips 
used for GWAS do not cover the closer SOCS-1 and - 3 genetic region, the specific aims in 
this study were to define the prevalent single nucleotide polymorphisms present in SOCS-1 
and - 3 in a cohort of volunteers donating blood and then to examine whether these 
polymorphisms may be linked to HIV progression rate.   
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Material and Methods: 
Swiss HIV Cohort study  
The Swiss HIV Cohort study (SHCS), established in 1988, is a systematic longitudinal study 
enrolling HIV-infected patients in Switzerland. The patients in the SHCS have given their 
informed consent for genetic testing, and we have obtained the samples for this study from the 
biobank of the SHCs.  
As we did in a previous In a previous study HIV-infected patients from the SHCS had been 
categorized according to the decline in CD4 counts: slow progressors, intermediate 
progressors and rapid progressors [21, 22]. The categories were created in two steps. First we 
estimated for each patient the CD4 decline over time before start of any ART. Second, we 
grouped the patients by tertiles of CD4 decline (top 33% of stepest decline being the rapid 
progessors, and the lowest 33% in decline being the slow progresssors). Thus, the rapid 
progressor group had an annual decline of CD4 cells larger than 101.5, and the slow 
progressor group of an annual decline of less than 31.7 cells/year before ART start. For 
patients with <2 CD4+ T-cell measurements between baseline and start of any ART we could 
not estimate a decline, and we exlcuded them (n = 69). Additional 24 patients without RNA 
measurements in the 18 months before HAART start (or st p date) have been excluded as 
well, resulting in a total of 1,051 patients fulfilling the criteria of < CD4+ T-cell and RNA 
measurements. The number of patients included in our analyses was n=1144 for which DNA 
could be obtained. Hence this sample is representative of the overall SHCS patient population 
(Table 1). 
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Single nucleotide polymorphisms (SNP) and haplotypes Analysis 
Screening for Polymorphisms in SOCS--1 and SOCS-3 in the General Population 
We screened 96 DNA samples collected from healthy Swiss blood donors (Swiss Red Cross 
Zurich, https://www.blutspendezurich.ch/) by denaturing high pressure liquid chromatography 
(dHPLC) [23] for identifying the variations of SOCS-1 and SOCS-3 genes in our target 
population using the WAVE DNA fragment analysis system (Transgenomic, Berlin, 
Germany). These genes are located on chromosomes 16 and 17, SOCS-1: 16p13.13 and 
SOCS-3: 17q25.3, respectively. Screening covered th coding region and the intron-exon 
boundaries, and 1.5kb upstream and 1kb downstream of the genes. This screening detected 
the following variations in the Swiss population: SOCS-1 rs193778, rs243330, rs193779, 
rs33989964, rs33977706, rs4780355; and SOCS-3 rs8064821, rs7207782, rs563935021, 
rs199915361, rs4969169, rs4969168, rs12185261. 
 
Genotyping and Haplotype Analysis of the Polymorphisms in SOCS-1 and SOCS-3 in the 
General Population  
To genotype the 13 detected variations, we established genotyping assays by High Resolution 
Melting (HRM) technique and fluorescence resonance energy transfer (FRET) on a 
LightCycler 480 II instrument (Roche, Switzerland), and by allele specific amplification 
(ASA) on agarose gels [24]. Haplotype frequencies were estimated with the software 
Haploview [25]. 
Genotyping of additional 176 DNAs from healthy Swiss blood donors revealed that two 
polymorphisms are inherited together with other polymorphism in healthy Swiss volunteers 
and two are rare, limiting the informative polymorphisms to 5 polymorphisms for SOCS-1 
and 4 polymorphisms for SOCS-3 (Supplementary Table, http://links.lww.com/QAI/B441).  
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Statistical Analysis in Rapid and Slow Progressors 
In all the conducted analyses we compared the rapid progressors (n=318) to the slow 
progressors (n=376).  For univariate comparisons of these groups, we used chi-square 
statistics for categorical information and t-tests for continuous information.  
We performed two different analyses, one comparing apid progressors to slow progressors 
with regard to SNPs in SOCS-1 and SOCS-3, and a second omparing the two groups with 
regard to haplotypes. In both of these analyses, we fitted multivariate logistic regression 
models, and report odds ratios and 95% confidence itervals. The model included sex, binary 
risk group (intravenous drug user (IDU) vs. non-IDU), quintiles of baseline CD4 and quintiles 
of baseline viral load. The SNP based analyses contained three genotype groups: homozygote 
genotype (AA - reference), heterozygote (AB or BA) and the less frequent versions of the 
homozygote genotypes (BB).   
In the analysis of haplotypes we first tested for linkage disequilibrium using Haploview [25]. 
Haplotypes were inferred using an expectation-maximization algorithm implemented in the 
SNPHAP program (version 1.3.1, developed by David Clayton) (https://www-
gene.cimr.cam.ac.uk/staff/clayton/software/snphap-1.3.1.zip). 
Sensitivity analyses were performed with rapid progressors versus all other (intermediate and 
slow progressor group combined), as well as including only Caucasian people and recessive 
models for the analysis of SNPs (homozygote genotypes BB versus all other (AA, AB/BA)). 
All analyses were performed using STATA® version 13.1. College Station, TX: StataCorp 
LP, 2013] and p-values <0.05 were considered as stati tic lly significant.  
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Results:  
Patient’s Characteristics 
Participants in the genetic study were mainly male Caucasians (74%) with a median age of 36 
years, similar to those included in the entire Swiss HIV Cohort Study (Table 1). The three 
main risk groups for HIV infection were homosexuals (41% in the genetic cohort and 32% in 
the general cohort), heterosexuals (36% and 31%) and intravenous drug users (12% and 23%). 
Identification of SOCS-1 and SOCS-3 Polymorphisms 
To identify polymorphisms in the SOCS-1 and SOCS-3 genes, we screened the promoter, the 
coding region, and the 3’UTR region of SOCS-1 and SOC -3 in in a representative 
population of 96 healthy Swiss blood donors. Subsequently, we selected five SNPs in SOCS-
1 and four SNPs in SOCS-3 with a minor allele frequency of more than 0.05 for the analysis 
with the progressor status in the Swiss HIV Genetic Cohort. Analysis of these SNPs in the 
Swiss HIV Genetic Cohort revealed that all SNPs are in Hardy-Weinberg equilibrium (Table 
2). All SNPs with negative values are located in the promoter region of the gene, while 
rs4780355 (c.*842A>G) and rs4969169 (c.*589A>G) arelocated in an intron and in the 3’ 
UTR, respectively. 
 
Association of SOCS-1 with the Rapid Progressor Phenotype 
To investigate the association of SNPs in SOCS-1 and SOCS-3 with the HIV progressor 
phenotype, we divided the Swiss HIV Genetic Cohort into three groups of slow progressors, 
intermediate progressors, and rapid progressors according to the decline in CD4 counts [21, 22]. 
Comparison of the rapid and slow progressor subgroups showed clearly the distinct CD4+ T-
cell decline rate and that the distribution of the ethnicities is similar (Table 3). 
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Four SOCS-1 SNPs were associated with the rapid progressor phenotype (Table 4). When 
using genotypes, the OR was 0.39 (0.16, 0.96) for rs193779 TT versus CC, 0.34 (0.15, 0.81) 
for rs33989964  CA/CA versus -/-, 2.22 (1.06, 4.65] for rs33977706 TT versus GG , and 0.47 
(0.25,0.90) for rs4780355 GG versus AA. Similar associations but with slightly higher 
significance were obtained when using a recessive allelic mode of inheritance (data not 
shown). In contrast, no association of these polymorphisms was detected with the viral load at 
the initial visit. To investigate whether a potential bias in ethnicities could interfere with the 
analysis, we performed a sensitivity analysis using whites only. We observed that the 
directions of the associations and the ORs are similar when looking at  whites only to the 
results obtained when including all ethnicities (data not shown). In addition, we performed as 
sensitivity analysis the multivariate logistic regrssion of rapid progressors versus all others 
(intermediate and slow) and also obtained similar results (data not shown). 
The three SOCS-1 SNPs rs193779, rs33989964, and rs4780355 show a similar risk reduction 
for the rapid progressor phenotype of approximately 60%, suggesting that some of these SNPs 
may be in linkage disequilibrium. We therefore investigated the linkage disequilibrium 
between all the SNPs (Suppl. Table 1, http://links.lww com/QAI/B441) and analyzed the 
association of the haplotypes with the progressor phenotype (Table 5). We observed a linkage 
between rs33989964 and rs4780355 with an r2 of 0.7, while none of the other SNPs were in a 
strong linkage disequilibrium. Accordingly, the minor alleles of these two SNPs convene on 
the frequent AC+GG haplotype, which is in homozygous carriers also associated with a risk 
reduction for the rapid progressor phenotype. 
In contrast to the three SOCS-1 SNPs associated with a r sk reduction for the rapid progressor 
phenotype, the minor TT genotype of rs33977706 is associated with twice the risk for the 
rapid progressor phenotype. Haplotype analysis reveal d that the minor allele of this SNPs is 
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mainly observed on the GC-TA haplotype, distinct from the AC+GG haplotype associated 
with the risk reduction. Consequently, we also observed a borderline increased risk for 
homozygous carriers of this GC-TA haplotype for the rapid progressor group (Table 5). 
No associations have been observed for the four SOCS-3 polymorphisms or for the major 
SOCS-3 haplotypes (Tables 4 and 5). 
 
Discussion: 
Progressive natural HIV infection is characterized by chronic IFN-α and -γ signaling. This 
chronic IFN activation is thought to contribute to proliferation and activation of CD4+ T-cells 
thereby increasing the number of available HIV target cells while promoting T-cell 
exhaustion, eventually resulting in a perpetuating vicious cycle. Notably, IFN signaling is 
attenuated by negative feedback regulators, among others SOCS-1 and SOCS-3. Here, we 
wondered whether distinct polymorphism(s) in SOCS-1 and 3 are associated with HIV 
progression rate by comparing rapid vs slow progressors. We found i) several SNPs in the 
gene region of SOCS-1 and 3 -in healthy volunteers and ii) three SNPs to be directly 
associated and one SNP to be inversely associated wi h HIV progression rate. These data are 
consistent with impact of HIV-mediated IFN signaling being critical in HIV pathogenesis. 
SNPs of SOCS--1 and -3 have not been thoroughly sought for in Caucasians and only a few 
SNPs in their gene region have been described but none in the promoter or coding region. 
Thus, we screened first 96 volunteers for SNPs in SOC -1 and -3 and found a large number 
of SNPs in the promoter and coding region of SOCS-1 and -3 (Table 2). We focused on the 
SNPs with an allelic frequency higher than 5%, which were not inherited together to 100% in 
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the general population to investigate their associati n with natural HIV disease progression in 
the genetic cohort study of the SHCS (Table 2).  
We found that four polymorphisms of SOCS-1 were associated with rapid progression of HIV 
but none in SOCS-3. However, the polymorphisms did not show any association with the 
viral load at the initial visit. Thus, the effects by the SOCS-1 and -3 feedback regulators 
appears to be uncoupled from viral load, i.e., the SNPs identified may have primarily an effect 
on the intricate process of CD4+ T-cell depletion but not at first hand on extent of viral 
replication. This comes back to the egg and hen problem whether immune activation drives 
CD4+ T-cell depletion and viral replication, or vice versa, viral replication drives immune 
activation and CD4+ T-cell depletion, or whether different mechanism(s) underlie those 
pathogenic events. It might even be that all three settings exist with one being more dominant 
than the other at different stages in HIV pathogenesis. This would explain the controversies in 
the literature. The lack of any association with SOCS-3 is rather astonishing in view of the 
data of SOCS-1. We might explain this selective association with SOCS-1 by the higher 
hierarchical role of SOCS-1 in attenuating rather all cytokines using Janus kinases [26]. These 
data corroborate the imminent role of IFN and other pathways in HIV pathogenesis.   
The association of allelic variants of SOCS-1 has been explored in a variety of diseases, 
among others in allergic and inflammatory diseases, metabolic diseases, as well as in cancer 
(Suppl. Table 2, http://links.lww.com/QAI/B441). However, the results from these studies did 
not reveal an obvious genetic denominator SNP in SOC -1 with an effect on disease outcome 
but rather indicated that the genetic locus may be associated with the investigated diseases. 
This is caused by the broad range of SNPs and haplotypes analyzed in these studies covering 
a large genetic region encompassing SOCS-1, which were often different between studies, 
and by the limited power of most studies to detect polygenic effects. In lack of corroborating 
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associations of one SNP or haplotype with disease, studies to investigate a potential functional 
effect of two SOCS-1 SNPSs have been performed. The study by Harada et al. showed that 
the del (-) allele at rs33989963 has increased SOCS-1 protein levels in human primary nasal 
fibroblasts and heterozygous carriers of the deletion had a higher risk for adult asthma [27]. 
Similarly, the T-allelic variant of rs33977706 within the SOCS-1 promoter increases the 
transcriptional activity of the SOCS-1 gene in transfection experiments and was associated 
with lower IgE levels in plasma [29]. In our analysis, we observed associations in opposite 
directions for these two SNPs with a potential functional increase in SOCS-1 activity, one 
associated with the rapid progressor phenotype and the other associated with the slow 
progressor phenotype. However, there is only mechanistic data for increased SOCS-1 protein 
activity for rs33989963 where the del (-) allele showed increased SOCS-1 protein levels and 
reduced STAT-1 phosphorylation [27]. Such an increased SOCS-1 activity that results in a 
more efficient attenuation of the Jak/STAT pathway nd is associated with the slow 
progressor phenotype would argue that preserved triggering via the IFN axis is beneficial to 
HIV infection.  
However, what a less prominent ISG response finally means remains unknown – we might 
speculate that a less prominent ISG response promotes viral replication; on the other side, a 
less prominent ISG response should trigger less immune activation. In fact, the role of IFNs in 
HIV remains highly disputed [3]. For further defining the role of SOCS-1 in HIV infection, a 
quantitative analysis of SOCS-1 protein would need to be done. This task is very demanding 
because of their transient nature and their manifold nf uences they are subjected to - a single 
snapshot analysis would not be meaningful. Alternatively, an interventional study would be 
attractive modulating SOCS-1. This remains hypothetical since such compounds are lacking 
[27].    
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We are aware of the ongoing debate about the value of candidate gene approaches as opposed 
to GWAS [28, 29]. It might be argued that multiple testing in studies using candidate gene 
approach might provide false positive results; thus the data obtained in our cohort need to be 
validated in other cohort of HIV-infected patients. On the other hand, GWAS are as good as is 
the coverage of the annotations of the genes and both SOCS genes are badly covered on the 
SNP chips. We consider the approaches complementary, imminent for getting a deeper insight 
into HIV pathogenesis and as first step for explorative studies. 
In summary, SNPs in SOCS-1 are associated with HIV disease progression rate, pointing to 
the imminent role the Jak/STAT axis has in HIV pathogenesis. In addition, allelic variants of 
SOCS-1, with either decreased or increased transcriptional activity of SOCS-1 go along with 
slow and rapid progressor status, respectively. The latt r findings imply that attenuating the 
Jak/STAT pathway favors HIV progression rate. Notwithstanding, we lack clinical studies 
which specifically interfere with the IFN axis for ultimate proof of its pathogenic significance.  
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Table 1: Characteristics of Patients included in the Genetic Study and the Swiss HIV Cohort 
Study 
 
  
Genetic Cohort 
(n=1144) 
General Cohort 
(n=12'285) 
Gender Males 0.74 0.71 
 Females 0.26 0.29 
Age (initial visit) Median 36 32 
Ethnicity White 0.879 0.63 
 Black 0.087 0.071 
 Asian 0.017 0.018 
 Hispano-American 0.014 0.011 
 Other 0.003 0.001 
 Unknown 0 0.27 
Risk group factor Homosexual 0.414 0.32 
 Heterosexual 0.363 0.31 
 Intravenous Drug User 0.122 0.23 
 Drug & Sex 0.066 0.1 
 Hemophilia 0.002 0.004 
 Transfusion 0.007 0.008 
 Other 0.009 0.005 
 Unknown 0.017 0.018 
CDC Stage (initial visit) A 0.868 0.68 
 B 0.078 0.19 
 C 0.054 0.13 
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Table 2: Genotypes in the genetic cohort study (n=1144) 
 
SOCS1  Genotypes        Frequencies P-HWE 
rs243330  GG                 0.24 
c.-1106G>A  GA                 0.52 
AA                 0.24      1.0 
rs193779  CC                 0.64 
c.-1080C>T  CT                 0.31 
TT                 0.04       0.78 
rs33989964  CA/CA          0.55 
c.-928_-927delCA CA/-              0.40 
-/-                   0.06      1.0 
rs33977706  GG                 0.55 
c.-270G>T  GT                 0.38 
TT                 0.07      0.82 
rs4780355  AA                 0.42 
c.*842A>G  AG                 0.48 
GG                 0.10      0.98 
 
SOCS3  Genotypes        Frequencies   P-HWE 
rs8064821  GG                 0.70 
c.-1649G>T  GT                 0.28 
TT                 0.02      0.69 
rs7207782  CC                 0.41 
c.-1636C>T  CT                 0.44 
TT                 0.15      0.25 
rs199915361  GG                0.88 
c.-747delG  G/-                 0.11 
-/-                   0.01      0.65 
rs4969169  GG                 0.87 
c.*589A>G  AG                 0.12 
AA                 0.01      0.56 
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Table 3: Characteristics of rapid and slow progressors 
 
  
Rapid progressors 
(n=318) 
Slow progressors 
(n=376) 
Gender Males 0.80 0.69 
 Females 0.20 0.31 
Age (initial visit) Median 38 32 
Ethnicity White 0.87 0.86 
 Black 0.10 0.093 
 Asian 0.016 0.024 
 Hispano-American 0.006 0.018 
 Other 0.003 0.003 
 Unknown - - 
Risk group factor Homosexual 0.50 0.34 
 Heterosexual 0.37 0.37 
 Intravenous Drug User 0.063 0.19 
 Drug & Sex 0.044 0.074 
 Hemophilia 0.003 0.003 
 Transfusion 0.000 0.010 
 Other 0.006 0.008 
 Unknown 0.013 0.008 
CDC Stage (initial visit) A 0.86 0.93 
 B 0.094 0.048 
 C 0.047 0.016 
Viral load* ln 10.4 (9.3-11.4) 9.1 (7.7-10.5) 
 log10 4.5 (4.0-4.9) 4.0 (3.3-4.6) 
Difference in CD4 per 
year* Slope -141 (-289,-11) 
 
-32 (-55,-14)** 
* The median (p25,p75) is shown. ** p<0.05 
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Table 4: Multivariate logistic regression model to investigate the association of 
polymorphisms in SOCS1 and SOCS3 with rapid versus slow progressor status (n=694) 
 
SOCS1  Genotype            OR    p-value        [95% CI] 
rs243330  GG                    1                            
c.-1106G>A   GA                  1.13     0.61      0.72,1.76            
AA                  0.84     0.51           0.49,1.42            
rs193779  CC                    1                            
c.-1080C>T   CT                  1.32     0.18      0.88,1.99            
TT                  0.39     0.041          0.16,0.96            
rs33989964  CA/CA                 1                            
c.-928_-927delCA  CA/-                1.02     0.92           0.69,1.50            
-/-                 0.34     0.014          0.15,0.81            
rs33977706  GG                    1    
c.-270G>T   GT                  0.92     0.69      0.62,1.37            
TT                  2.22     0.034          1.06,4.5            
rs4780355  AA                    1                                  
c.*842A>G   AG                  0.97     0.87      0.65,1.44            
GG                 0.47     0.023          0.25,0.90            
 
SOCS3   Genotype           OR    p-value         [95% CI] 
rs8064821  GG                    1                            
c.-1649G>T   GT                  0.79     0.27      0.52,1.20            
TT                  1.53     0.56           0.37,6.23            
rs7207782  CC                    1                            
c.-1636C>T   CT                  0.93     0.71      0.62,1.39            
TT                  0.76     0.34           0.43,1.4            
rs199915361  GG                    1                                  
c.-747delG   G/-                 1.21     0.51      0.69,2.13            
-/-                 1.34     0.79           0.15,11.75            
rs4969169  GG                    1                            
c.*589A>G   AG                  0.98     0.95      0.56,1.74            
    AA                  3.28     0.34           0.29,37.77                     
Multivariate logistic regression model including gend r, quintiles of 
baseline CD4 values, quintiles of baseline viral lod and IDU. 
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Table 5: Multivariate logistic regression model to investigate the association of 
haplotypes in SOCS1 and SOCS3 with rapid versus slow progressor status (n=694) 
 
SOCS1 Frequency* OR (95% CI)   p-value 
GC-TA       0.266  0.96 (0.65, 1.42)  0.84** 
hom    2.12 (0.98, 4.56)  0.056** 
AC+GG     0.262    1.01 (0.68, 1.49)  0.97** 
hom    0.34 (0.14, 0.80)  0.014**  
AC-GA       0.193    
GT-GA       0.184    
AC-GG       0.043     
GC-GA       0.020   
GT-GG       0.015   
GC-GG       0.014   
Others  0.033            
 
 
SOCS3 Frequency* OR (95% CI)   p-value 
GT+G       0.366  0.94 (0.63, 1.40)  0.75** 
hom    0.73 (0.41, 1.29)    0.28** 
GC+G        0.347  1.22 (0.82, 1.81)  0.33** 
hom    1.21 (0.67, 2.21)    0.53** 
TC+G        0.147 
GC+A        0.079 
GC-G        0.058 
Others  0.030         
                     
Multivariate logistic regression model including gend r, quintiles of 
baseline CD4 values, quintiles of baseline viral lod and IDU. The 
haplotypes are named according to the sequence of th  alleles observed 
along the chromosome at the analyzed SNPs. The order f the SNPs is 
shown in table 4 from top to bottom. For SOCS-1 five SNPs have been 
genotyped leading to a five position haplotype name, while for SOCS-3 four 
SNPs have been analyzed leading to a four position haplotype name. +, CA 
allele of rs33989964. -, del (-) allele of rs33989964.hom, homozygous 
diplotype. *Overall haplotype frequency in the cohort. ** Additive genetic 
model versus all other haplotypes. 
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